AG 555

AG 555 (Tyrphostin AG 555), a potent antiretroviral drug, is a potent and selective inhibitor of EGFR and blocks Cdk2 activation.

Product information

CAS Number: 133550-34-2

Molecular Weight: 322.36

Formula: C19H18N2O3

Synonym:

Tyrphostin AG 555

Chemical Name: (2E)-2-cyano-3-(3, 4-dihydroxyphenyl)-N-(3-phenylpropyl)prop-2-enamide

Smiles: N#C/C(=C\C1=CC(O)=C(O)C=C1)/C(=O)NCCCC1C=CC=CC=1

InChiKey: GSQOBTOAOGXIFL-LFIBNONCSA-N

InChi: InChI=1S/C19H18N2O3/c20-13-16(11-15-8-9-17(22)18(23)12-15)19(24)21-10-4-7-14-5-2-1-3-6-14/h1-3,5-6,8-9,11-12,22-23H,4,7,10H2,(H,21,24)/b16-11+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 100 mg/mL (310.21 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

AG 555 (100 μM) inhibits both the early stages (integration process) and the late stages (viral protein synthesis) in the virus life cycle. Tyrphostins AG555, which blocks Cdk2 activation, induces growth arrest of immortalized cells at G1-S and early S and is very effective in arresting the growth of EGFR overexpressor cells. Tyrphostin AG 555 can selectively suppress BPV-1 transcription through MAP kinase pathway activation and binding of phosphorylated Jun/ATF-2 at a novel intragenic regulatory sequence.

References:

1. Seri E Aflalo, et al. Tyrphostin AG-555 inhibits early and late stages of Moloney murine leukemia virus replication cycle. International Journal of Oncology. 1997.
2. Nir Osherov, et al. Tyrphostin AG494 blocks Cdk2 activation Nir Osherov. FEBS Letters 410 (1997) 187-190
3. Sabine Baars, et al. Tyrphostin AG 555 Inhibits Bovine Papillomavirus Transcription by Changing the Ratio between E2 Transactivator/Repressor Function. Vol. 278, No. 39, Issue of September 26, pp. 37306–37313, 2003.

Products are for research use only. Not for human use.